104,346 Shares in Scholar Rock Holding Corporation $SRRK Acquired by Man Group plc

Key Points

• Man Group plc acquired 104,346 shares of Scholar Rock worth approximately $5.74 million, while institutional investors collectively own 91.08% of the company.
• Scholar Rock reported quarterly EPS of -$0.84, in line with analyst expectations; analysts project full-year EPS of approximately -$3.23.
• Analyst sentiment remains broadly positive, with a consensus “Buy” rating and an average price target of $58.77, although insiders sold 17,149 shares worth $923,108 during the last quarter.

Man Group plc acquired a new stake in shares of Scholar Rock Holding Corporation (NASDAQ:SRRK - Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 104,346 shares of the company's stock, valued at approximately $5,739,000. Man Group plc owned about 0.09% of Scholar Rock as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. GAMMA Investing LLC increased its holdings in Scholar Rock by 20.8% during the second quarter. GAMMA Investing LLC now owns 1,406 shares of the company's stock valued at $77,000 after buying an additional 242 shares during the last quarter. Values First Advisors Inc. raised its position in Scholar Rock by 1.5% in the first quarter. Values First Advisors Inc. now owns 18,850 shares of the company's stock worth $927,000 after acquiring an additional 286 shares during the period. IFP Advisors Inc boosted its stake in shares of Scholar Rock by 294.1% during the 4th quarter. IFP Advisors Inc now owns 603 shares of the company's stock worth $27,000 after acquiring an additional 450 shares during the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of Scholar Rock by 151.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company's stock worth $38,000 after acquiring an additional 525 shares during the last quarter. Finally, California State Teachers Retirement System grew its position in shares of Scholar Rock by 0.9% during the 2nd quarter. California State Teachers Retirement System now owns 62,372 shares of the company's stock valued at $2,209,000 after acquiring an additional 577 shares during the period. Institutional investors own 91.08% of the company's stock.

Scholar Rock Trading Down 2.5%

SRRK opened at $57.80 on Friday. The company has a debt-to-equity ratio of 0.77, a quick ratio of 7.02 and a current ratio of 7.02. The stock's 50 day moving average price is $53.07 and its 200-day moving average price is $48.90. Scholar Rock Holding Corporation has a one year low of $27.07 and a one year high of $61.76. The stock has a market cap of $7.04 billion, a price-to-earnings ratio of -16.75 and a beta of 0.69.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.84) earnings per share for the quarter, hitting the consensus estimate of ($0.84). During the same period in the prior year, the company earned ($0.98) EPS. On average, equities analysts forecast that Scholar Rock Holding Corporation will post -3.23 EPS for the current year.

Insider Activity

In other news, Director Michael Gilman sold 2,544 shares of Scholar Rock stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $53.87, for a total value of $137,045.28. Following the transaction, the director owned 59,511 shares of the company's stock, valued at $3,205,857.57. The trade was a 4.10% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jeffrey S. Flier sold 3,053 shares of Scholar Rock stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $53.88, for a total transaction of $164,495.64. Following the completion of the transaction, the director directly owned 27,856 shares in the company, valued at $1,500,881.28. This represents a 9.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 17,149 shares of company stock valued at $923,108. 10.30% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on SRRK shares. Barclays raised their target price on shares of Scholar Rock from $53.00 to $55.00 and gave the stock an "overweight" rating in a research note on Friday, May 8th. JPMorgan Chase & Co. raised their price objective on shares of Scholar Rock from $56.00 to $63.00 and gave the company an "overweight" rating in a research report on Thursday, August 13th. Citigroup upped their target price on shares of Scholar Rock from $58.00 to $60.00 and gave the stock a "buy" rating in a report on Friday, August 7th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Scholar Rock in a research note on Friday, July 17th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Scholar Rock in a research report on Thursday, June 18th. Four research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $58.77.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company's research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock's approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company's lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source